<link rel="stylesheet" type="text/css" href="https://ubosquemoodle.unbosque.edu.co/theme/uebtheme/css/stylesUEB.css">
<link rel="stylesheet" type="text/css" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/css/styles.css" />


<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/Menu/menu-local.js" type="text/javascript"></script>
<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js" type="text/javascript"></script>
<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js" type="text/javascript"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/Menu/timeit.js" type="text/javascript"></script>

<link rel="stylesheet" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/dist/css/lightbox.min.css" />

<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/dist/js/lightbox-plus-jquery.min.js" type="text/javascript"></script>


<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>

<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js"></script>

<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js"></script>

<!-- ================== script ================== -->
<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>

<!-- ================== lightbox ================== -->




<!-- ================== animate scroll ================== -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/animate.css/3.5.1/animate.min.css">
<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/wow/1.1.2/wow.min.js"></script>



<!-- ================== fin animate scroll ================== -->

<!-- ================== css ================== -->
<link rel="stylesheet" type="text/css" href="../css/styles.css">


<!-- ================== contenido ================== -->
<div class="curso-cc mod3" id="pagina10">
	
	<!-- ================== 2º nivel ================== -->
	<div class="container-fluid">
	<div class="row-fluid" id="menu-numero-1">
		
	</div>
	</div>
	<!-- ================== end 2º nivel ================== -->
	
	<!-- ================== 1º nivel ================== -->
	<div class="container-fluid">
		<div class="row-fluid">
			<div class="span12 banner-cursos" id="banner-mod-3"></div>
		</div>
	</div>
	<!-- ================== end 1º nivel ================== -->
	
	<!-- ================== 3º nivel ================== -->
	<div class="container-fluid">
	<div class="row-fluid">
		<!-- contenido -->
		<div class="span12 content-cc" >
			
			<h2>Capítulo 3 / <span> Bibliografía</span></h2>
			
			<ol>
				<li>Cholesterol Treatment Trialists’ (CTT) Collaboration. 2015. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in randomised trials. Lancet., 385: 1397–405.</li>
				<li>Cannon CP, Steinberg B, Murphy S, Mega J, Braunwald E, et al. 2016. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol., 48:438-445.</li>
				<li>Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, et al. 2017.  Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology (AAEC/ACE) on the comprehensivety type 2 diabetes management algorithm-2017 execu</li>tive summary. Endocrin Pract., 23:207-238.
				<li>Merchan A, Jaramillo C, Mendoza F, Agudelo F. 2008. ¿Se están alcanzando las metas en el perfil lipídico después de enfermedad coronaria? Rev Colomb Cardiol.,18:262-267.</li>
				<li>Alkindi M, Siminovitch KA, Gupta M and Genest J. 2016. Monoclonal antibodies for the treatment of hypercholesterolemia: targeting PCSK9. Canadian J Cardiol.,32:1552-1560.</li>
				<li>Artenstein AW and Opal SM. 2011. Proprotein convertases in health and diseases. NEJM., 365:2507-2518.</li>
				<li>Norata GD, Tavori H, Pirillo A, Fazio S, and Catapano AL. 2016. Biology of proprotein convertase subtilisin kesin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovascular Research. , 112(1):429-442.</li>
				<li>Boileau C, and Abifadel M. 2016. The PCSK9 story. Eur Heart J.,37:1341-1352.</li>
				<li>Abifadel M, Varret M, Rabés JP, Allard D, Duguerram K, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet.,34:154-156.</li>
				<li>Poirier S and Mayer G. 2013. The biology of PCSK9 from the endoplsmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Design, Development and therapy., 7:1135-1148.</li>
				<li>Merchan A, Ruiz A, Campo R, Prada CE, Toro JM, et al. 2016. Hipercolesterolemia familiar: artículo de revisión. Rev Colomb Cardiol.,23(S4):4-26.</li>
				<li>Cohen J, Pertsemildis A, Kotowski I, Graham R, Garcia C, et al. 2005. Low LDLc in individuals of African descendent resulting from frequent nonsense mutations in PCSK9. Nat Genetics., 37:161-165.</li>
				<li>Cohen JC, Boerwinkle E, Mosley TH and Hobbs HH. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. NEJM.,354:1264-1272.</li>
				<li>Goldstein, J. L., and M. S. Brown. 1977. The low density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 46:897-930.</li>
				<li>Goldstein JL, and Brown MS. 1984. Progress in understanding the LDL receptor and HMGCoA reductase, two membrane proteins that regulate the plasma cholesterol. Journal of Lipid Research.,25:1450-1461.</li>
				<li>Lagace T, Hammer RE, Horton JD. 2006. Secreted PCSK9 decreases the number of LDL receptor in hepatocytes and inlivers of mice. J Clin Invest.,116(11):2995-3005</li>
				<li>Peterson AS, Fong LG and Young SG. 2008. PCSK9 function and physiology. Journal of Lipid Research.,49:1595-1599.</li>
				<li>Tavori H, Fan D, Blakmore JL, Yancey PG, Ding L, et al. 2013. PCSK9 and cell surface low-density lipoprotein receptor. Evidence for a reciprocal regulation. Circulation.,127:2403-2413.</li>
				<li>Farnier M. 2014. PCSK9: from discovery to therapeutic applications. Archives of Cardiovascular disease.,107:58-66.</li>
				<li>Foltz IN, Karow M, Wasserman SM. 2013. Evolution and emergence of therapeutic monoclonal antibodies. What cardiologists need to know. Circulation.,127:2220-2230.</li>
				<li>Weiner LM. 2006. Fully human therapeutic monoclonal antibodies. J Immunolther. 29:1-9.</li>
				<li>Beck A, Wurch T, Bailly C, Corvaia N. 2002. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol.,10:345-352.</li>
				<li>Alkindi M, Siminovitch KA, Gupta M and Genest J. 2016. Monoclonal antibodies for the treatment of hypercholesterolemia: targeting PCSK9. Can J Cardiol.,32:1552-1560.</li>
				<li>Ecker DM, Jones SD, Levine HL. 2015. The therapeutic monoclonal antobody market. mAbs.,7(1):9-14.</li>
				<li>Adams-Sanchez ChD y Tobon-Garcia GJ. 2016. Terapia con anticuerpos monoclonales en cardiología y medicina interna. Rev Col Cardiol.,23(4):293-300.</li>
				<li>Chana JC, Piper DE, Cao Q, Liu D, King Ch, et al. 2009. A proprotein convertase subtilisin/kesin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhumans primates. PNAS. 106(24):9820-9825.</li>
				<li>Gusarova V, Howard VG, Okamoto H, KoehlerStec E-M, Papadopoulos N, et al. 2012. Reduction of LDL cholesterol by monoclonal antibody to PCSK9 in rodents and nonhuman primates. Clin Lipidol.,7(6):737-743.</li>
				<li>Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, et al. 2012. Effects of AMG 145 on low-density lipoprotein cholesterol levels. JACC.,60:1888-1892.</li>
				<li>Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. NEJM., 366:1108-1118.</li>
				<li>Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantrey U, et al. 2015. Effects of PCSK9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis. Ann Intern Med.,163:40-51.</li>
				<li>Ghadban R, Enezate T, Omran J, Almourani R, Singla A, et al. 2017. Clinical outcomes of PCSK9Is: a meta-analysis of randomized clinical trials. Cardiovasc Diagn Ther.,7(6):598-606.</li>
				<li>Tsujita K, Sugiyama S, Sumida H, et al. 2015. Impact of dual lipid lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention. The multicenter randomized controlled PRECISE-IVUS Trial. JACC.,66:495-507.</li>
				<li>Nicholls SJ, Puri R, Anderson T, et al. 2016. Effect of evolocumab in progression of coronary disease in statin-treated patients. The GLAGOV randomized clinical trial. JAMA.,316:2373-2384.</li>
				<li>Puri R, Nissen S, Shao M, Ballantyne ChM, Barter PJ, et al. 2013. Coronary ateroma volumen and cardiovascular events during maximally intensive statin therapy. Eur Heart J.,34:3182-3190.</li>
				<li>Sabatine MS, Giugliano RP, Keech AC, et al. 2017. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med.,376:1713-1722.</li>
				<li>Giugliano RP, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA, Ceska R, et al. 2017. Clinical efficacy and safety of achieving very low LDL cholesterol concentrations with evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet.,390:1962-1971.</li>
				<li>Cchwartz GC, Bessae L, Berdan LG, et al. 2014. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. AM Heart J.,168:682-689.</li>

			</ol>
			
			
			<!-- new row inside barra progreso -->
			<div class="row-fluid">
				<div class="span12">
					<h2>Capítulo 3 / <span>Progreso</span> </h2>
				</div>
				<div class="span12" id="progreso100"></div>
			</div>
			<!-- end new row inside -->
			
			<!-- new row inside material modulo -->
			<div class="row-fluid wow  fadeInUp  material-modulo">
				<div id="material-mod-3"></div>
			</div>
			<!-- end new row inside -->
			
			<!-- new row inside botones -->
			<div class="row-fluid">
				<ul class="pager">
				  <li class="previous">
				    <a href="https://ubosquemoodle.unbosque.edu.co/mod/page/view.php?id=252123"><i class="fa fa-caret-left" aria-hidden="true"></i> Anterior</a>
				  </li>
				  <li class="next disabled">
				    <a href="#">Siguiente <i class="fa fa-caret-right" aria-hidden="true"></i></a>
				  </li>
				</ul>
			</div>
			<!-- end new row inside -->
			
		</div>
			
		<!-- end contenido -->
	</div>
	</div>
	<!-- ================== end 3º nivel ================== -->
	
	<!-- ================== 4º nivel ================== -->
	<div class="container-fluid">
		<div class="row-fluid">
			<div class="span" id="footer"></div>
		</div>
	</div>
	<!-- ================== end 4º nivel ================== -->
	
</div>
<!-- ================== contenido ================== -->

<!-- ================== script ================== -->
<script src="../Menu/menu-local.js" type="text/javascript"></script>
<script src="../Menu/timeit.js"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/Menu/menu-local.js" type="text/javascript"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/Menu/timeit.js" type="text/javascript"></script>




<!-- ================== fin script ================== -->
<script>
$(".menu-toggle").click(function() {
  $("nav > ul").slideToggle( "700");
  $("nav > ul").css('display','flex');
});

$(document).ready(function(){
    $(window).scrollTop(0);
});
</script>

<script src="jquery.min.js"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/amgen/iframe-code/set-iframe-height-child.js"></script>

<!-- ================== script animate scroll ================== -->
<script>
	new WOW().init();
</script>
<!-- ================== fin script animate scroll ================== -->


<script src="http://code.jquery.com/jquery.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/2.3.2/js/bootstrap.min.js"></script>